相关实验视频

Updated: Jul 28, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

与产生抗体-表皮质结合体的方法进行比较,以病毒特异性T细胞向癌症

Willemijn van der Wulp¹, Anna M Gram¹, Boris Bleijlevens²

¹Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands.

Frontiers in immunology

|June 1, 2023

概括

抗体-表位合物 (AECs) 通过重定向T细胞,显示出癌症治疗的潜力. 优化结合策略和表位序列对于提高癌症治疗中的AEC疗效至关重要.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物结合化学生物结合化学

背景情况:

治疗性抗体-表位合物 (AEC) 提供了一种新的方法来利用病毒特异性的T细胞免疫力对抗癌症.
需要优化AEC设计以提高其治疗效果.

研究的目的:

评估不同的结合策略,以创建抗体-表位组结合物.
评估AECs在激活T细胞和调解癌细胞死亡方面的有效性.

主要方法:

结合爱斯坦-巴尔病毒 (EBV) 和细胞巨乳病毒 (CMV) 表位体与 cetuximab 和 trastuzumab 抗体,使用化学,酶 (排序 A) 和基因融合方法.
评估由产生的AECs介导的T细胞激活和杀目标细胞.

主要成果:

所有测试的AEC都成功地激活了T细胞,并通过表位的蛋白质解释诱导了细胞的杀死.
抗体向表达对T细胞激活至关重要.
链体的氨基酸序列影响了表位素传递效率.

结论:

不同的结合策略可以产生功能性AEC,能够使癌细胞对病毒特异性T细胞敏感.
为了优化基于AEC的疗法,需要进一步选蛋白酶分裂部位和表位.

关键词:

抗体-表位合物 (AECs) 是一种抗体-表位合物结合策略结合策略免疫疗法免疫疗法重定向病毒特异性的T细胞.有针对性的治疗.

更多相关视频

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...